Full-length IgG display answers a question the smaller antibody formats cannot: how will the actual therapeutic molecule behave? Most discovery platforms work in scFv or Fab format because those fragments are easy to display, and most leads are eventually converted to full-length IgG for the clinic. The conversion step is where surprises hide. Displaying and selecting in full-length IgG on mammalian cells removes that risk by making the discovery format and the product format the same thing.
What full-length IgG requires
A therapeutic IgG is not a scaled-up fragment. It is two heavy chains and two light chains assembled with the correct inter-chain disulfides, an Fc domain glycosylated at the conserved N297 site, and effector function mediated by that Fc through Fcγ receptors and complement. Three of those properties — four-chain assembly, native disulfide architecture, and Fc glycosylation — are mammalian-cell capabilities. Yeast and phage can present binding fragments, but they cannot assemble and modify a full IgG the way a human-like cell does. The post-translational machinery involved is the same one that shapes developability, as we discuss in post-translational modifications in mammalian protein production.
The cost of reformatting
The standard discovery-then-reformat workflow looks efficient and often is not. An scFv or Fab hit selected on a fast platform is converted to IgG, and only then are its real properties measured. Common reformatting artifacts:
- Affinity shifts. A bivalent IgG gains avidity that a monovalent fragment lacked, or a linker-dependent scFv loses the geometry that drove its binding. Either way the ranked panel changes after reformatting.
- Expression drops. A fragment that displayed well can express poorly as full-length IgG, knocking out otherwise promising clones late.
- New liabilities. Aggregation, polyreactivity, and stability problems can appear only in the full molecule.
Each artifact is discovered after the reformatting cycle is spent. Selecting in full-length IgG from the start collapses discovery and format validation into one step.
How full-length IgG display works
The library is built as full-length heavy and light chains with a membrane anchor that tethers the assembled IgG to the cell surface, then integrated into CHO or HEK293 cells, typically with one variant per cell so binding signal can be read per clone.
- Library construction. Paired heavy and light chains cloned into a mammalian display vector with a surface-display anchor and quality-controlled by NGS.
- Integration and display. Single-copy genomic integration by viral or transposase delivery, a short expression window, then a display-level check by anti-IgG staining.
- FACS selection. Multi-round sorting against labeled antigen at increasing stringency, gating on display level so the sort selects affinity rather than expression. Counter-selection against off-targets as needed.
- NGS and hit calling. Enriched pools sequenced; clones ranked by enrichment and a panel expressed as soluble IgG for confirmation.
Because the displayed molecule is already a full-length IgG, the confirmed leads need no reformatting before developability and functional work.
CHO or HEK293
The host choice follows the program stage. HEK293 transfects efficiently and grows fast, which suits early library work and rapid validation. CHO is the regulatory-favored production host and the right choice for late-stage selection that must match manufacturing conditions. Many programs use HEK293 for the early rounds and a CHO round for final lead selection; the biological differences are covered in when CHO and HEK293 outperform yeast.
Where full-length IgG display fits
Full-length IgG display is not a naive-discovery engine — its library ceiling is well below yeast or phage. Its value is at the point where format fidelity matters most: validating and ranking a focused panel of leads in the exact molecule that will advance. The common pattern is the two-platform approach — discover and mature small formats on yeast display for diversity and speed, then move the short list onto full-length IgG mammalian display for developability and format-true selection.
If your program is heading toward a full-length antibody and you want the discovery format to match the product, see our mammalian display services and antibody engineering services, or start a project.
Related Ranomics services
- Mammalian display: Full-length IgG and glycosylation-dependent screening on CHO and HEK293.
- Antibody and nanobody engineering: Discovery, humanization, and maturation across formats.
- Yeast surface display: Fast, diverse discovery and maturation that pairs with IgG display for validation.
Frequently asked questions
Why display full-length IgG instead of scFv or Fab?
Because the molecule you select is the molecule you ship. Full-length IgG carries native heavy-light chain pairing, inter-chain disulfides, and Fc glycosylation that scFv and Fab formats lack. Selecting in IgG avoids the affinity, expression, and aggregation surprises that appear when a small-format hit is later reformatted to a full antibody.
What are reformatting artifacts?
When an scFv or Fab hit is converted to full-length IgG, its apparent affinity can drop as bivalent avidity is lost or gained, expression can fall, and new aggregation or stability liabilities can emerge. These artifacts are only discovered after the reformatting work is done, which wastes a cycle. Direct IgG selection removes that risk.
Which cell line is used for full-length IgG display?
HEK293 for fast library work and lead validation, CHO when the goal is to match a CHO production line for late-stage developability. Both provide the human-pattern glycosylation and four-chain assembly machinery that full-length IgG requires.
How large can a full-length IgG display library be?
Practically 10^5 to 10^7, set by transfection and sorting throughput rather than by the format. That is smaller than a yeast library, so full-length IgG display is best used on pre-filtered or focused panels rather than fully naive discovery.